Norgine BV - Company Profile

Powered by

All the data and insights you need on Norgine BV in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Norgine BV Strategy Report

  • Understand Norgine BV position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Norgine BV: Overview

Select Item

Norgine BV (Norgine), a subsidiary of Norgine Europe B.V develops, manufactures, and commercializes specialty pharmaceuticals and medical devices. The company's product portfolio spans branded drugs and devices in the areas of gastroenterology, hepatology, and cancer and supportive care. It also advances pipeline candidates for the treatment of various gastroenterological and hepatological diseases and disorders. Norgine serves healthcare systems and patients in Europe, New Zealand, and Australia. Its prominent partners include Takeda, Bausch Health, Abeona Therapeutics, Alfasigma, Amicus, China Medical System Holdings, Modi-Mundipharma, Navidea, Noventure, and Olympus Corp, among others. The company has subsidiaries in the UK, Italy, Germany, Portugal, Switzerland, The Netherlands, Austria, France, Belgium, Denmark, Spain, New Zealand, Australia, South Africa, and Egypt. Norgine is headquartered in Amsterdam, Noord-Holland, the Netherlands.

 Gain a 360-degree view of Norgine BV and make more informed decisions for your business Gain a 360-degree view of Norgine BV and make more informed decisions for your business Find out more
Headquarters Netherlands
Address Antonio Vivaldistraat 150, Amsterdam, Noord-Holland, 1083HP
Website www.norgine.com
Telephone 31 20 5670900
No of Employees 1,500
Industry Pharmaceuticals and Healthcare
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Norgine BV premium industry data and analytics

50+

Clinical Trials

Determine Norgine BV go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

20+

Marketed Drugs

Understand Norgine BV’s commercialized product portfolio to stay one step ahead of the market.

17+

Pipeline Drugs

Identify which of Norgine BV’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

7

Catalyst Calendar

Proactively evaluate Norgine BV’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

4

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

1

Sales & Consensus Forecasts

Understand the current and future drug revenue for Norgine BV and assess market opportunity for new entrants with patient population 8-year forecasts.

1

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Norgine BV’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Product Categories: Axid
Gastroenterology Products Destolit
Hepatology Products Endocuff Vision
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Norgine BV portfolio and identify potential areas for collaboration Understand Norgine BV portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Stake Sale In December, the company sold a majority stake to Goldman Sachs Asset Management.
2022 Contracts/Agreements In May, the company agreed to sell majority of sake to Goldman Sachs Asset Management, a provider of asset management services.
2021 Contracts/Agreements In July, the company entered into an exclusive licensing agreement with US WorldMeds to commercialize difluoromethylornithine, DFMO (eflornithine) in Europe, Commonwealth of Independent States, Australia and New Zealand.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Norgine BV Stada Arzneimittel AG RedHill Biopharma Ltd Theravance Biopharma Inc Protalix BioTherapeutics Inc
Headquarters Netherlands Germany Israel United Kingdom United States of America
City Amsterdam Bad Vilbel Tel Aviv-Yafo George Town Hackensack
State/Province Noord-Holland Hessen - Cayman Islands New Jersey
No. of Employees 1,500 13,183 113 111 193
Entity Type Private Private Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Executives
Name Position Board Since Age
Peter Stein Chairman Executive Board - -
Christopher Bath Chief Executive Officer Senior Management 2022 -
Saulo Martiniano Chief Operating Officer Senior Management 2023 -
Sheila Hopkins Chief Legal Officer Senior Management - -
David Gillen Chief Medical Officer Senior Management 2022 -
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Gain insight into Norgine BV key executives to enhance your sales strategy Gain insight into Norgine BV key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward